



# Becoming Australia's leading manufacturer & wholesaler of novel medicines

**ASX:BXN**

# Important Notice and Disclaimer



This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company).

The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subject to change without notice and, subject only to any legal obligations to do so, Bioxyne does not have any obligation to correct or update the contents of this Presentation.

The Presentation contains certain “forward-looking statements”. The words “forecast”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice and involve known and unknown risks and certainties and other factors which are beyond the control of Bioxyne, and its directors and management, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. Recipients are cautioned not to place undue reliance on forward-looking statements. Refer to the risk factors section of this Presentation for some of the key known risks. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation.

The forward-looking statements are based on information available to Bioxyne as at the date of this Presentation. Circumstances may change and the contents of this Presentation may become outdated as a result. Except as required by law or regulation, none of Bioxyne, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

No party other than Bioxyne has authorised or caused the issue, lodgement, submission, dispatch or provision at the end of this Presentation, or takes any responsibility for, or makes or purports to make any statements, representations or undertakings in this Presentation. To the maximum extent permitted by law, Bioxyne (including its subsidiaries, related bodies corporate, shareholders, affiliates, advisers and agents):

- disclaims all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation;
- disclaims any obligations or undertaking to release any updates or revision to the information in this Presentation to reflect any change in expectations or assumptions; and
- does not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this Presentation or the likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement.

## Not An Offer

This Presentation is not a prospectus, product disclosure document or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and should not be considered as, an offer, solicitation, inducement, recommendation or an invitation to acquire securities in Bioxyne or any other financial products, and neither this document nor any of its contents will form the basis of any contract or commitment.

This Presentation may not be distributed to any person in any country outside Australia except to the extent permitted under applicable laws. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice on such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

## Not Financial Product Advice

This Presentation is not financial product, investment advice or a recommendation to acquire Bioxyne securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including, but not limited to, the assumptions, uncertainty and contingencies which may affect future operations of Bioxyne and the impact that different future outcomes may have on Bioxyne. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Bioxyne is not licensed to provide financial product advice in respect of its securities or any other financial products.

# Investment Highlights



**Strong revenue growth**, recording a 119% lift to \$4.6m for Q1 FY25 on pcp, achieving cash flow positivity of \$1.2m



**Extensive Good Manufacturing Practice (GMP) licence** issued by TGA for medicinal cannabis products



**First company licensed by TGA** in Australia to manufacture Psilocybin & MDMA products




**Diversified core of healthcare & wellness revenue streams**, from supplements to psychedelic medicines



**Australian Cannabis market** is currently valued at an estimated ~\$1bn per year, a high-growth market



**Executed multiple supply agreements** with market leading cannabis suppliers, estimated to generate \$50m in sales across 2 years



**Growth opportunity** from highly scalable site & rapidly replicable pharmaceutical grade GMP manufacturing operations



**Capital-light, high-margin business model** focused on building enduring IP & brands

Positioned to become Australia's leading manufacturer of novel medicines & health products, with a core focus on cannabis products through its Breath Life Sciences (BLS) brand

## Bioxyne's Core Brands



**BREATHE LIFE SCIENCES**

B2B manufacturing and wholesaling of finished products and APIs



Medicines and consumer health product brands sold in Australia, Europe, UK and Japan

**\$4.6m**

Total Revenue for Q1 FY25, a 119% increase on Q1 FY24

**~36%**

FY24 Gross Profit Margin after all selling costs, up from 28% in FY23

Est. **\$36.5m**

in supply agreements for THC pastilles across 2 years

**\$20m+**


FY25 Revenue Target, anticipated to be EBITDA positive in H1'25



**Biocyte**

# Company Overview

# Commercial Milestones to Date



# Breathe Life Sciences' Supply Chain Model




<sup>1</sup> Australian Department of Health and Aged Care TGA – Medicinal Cannabis Authorised Prescriber Scheme Data

<sup>2</sup> Estimated prescriptions from 1 January 2023 – 30 June 2024

# Significant Market Opportunity

Bioxyne has established a global supply, manufacture and distribution network, now rapidly scaling revenues to service both the B2B & B2C market across all products.

- Estimated Market Size
- Suppliers
- Existing Distribution & Sales
- Near-term Market Entry
- Manufacturing & Distribution Facility
- Corporate & Sales Office







**Biocyte**

# Growth Strategy

# Near-Term Growth Strategy



**Exceed revenue guidance of \$20.0m**




**Secure new contracts to build on growing topline revenue growth**



**Continue to generate positive cashflow & EBITDA generation**



**Quickly scale and improve efficiencies to enhance margins**



**Materially increase production capability across all SKUs to meet market demand**



**Expand manufacturing capability in Czechia to meet European demand**



**Complete regulatory certification of Czechia-based facility**





**Deliver first revenues in mid-CY25 in both UK and European markets from new facility**

# Multiple High-Value Manufacture & Supply Agreements







Contracts for manufacture of key products continue to grow, with a total of \$47.5m in contracted pipeline of purchase orders


	Contract 1	Contract 2	Additional Contracts	Total Contracts
<b>Product</b>	THC & CBD Pastilles	THC & CBD Pastilles THC Flower	THC & CBD Pastilles THC Flower Vapes Oral Liquids / Oils	THC & CBD Pastilles THC Flower Vapes Oral Liquids / Oils
<b>Date</b>	August 2024	September 2024	Various	
<b>Number of Customers</b>	1	1	10	12
<b>Term</b>	24 months	12 months	Various	Various
<b>Total Contracted Revenue</b>	\$28m	\$3.6m	\$15.9m	\$47.5m



# Expanding Production Capability

Recent investment into additional equipment & facilities will provide substantial increased production capability at Australia sites

SKU	 THC Flower	 THC & CBD Pastilles	 Vapes	 Oral Liquids / Oils
Current Output (revenue per day)	\$34,000 – \$40,000	\$99,000	\$27,000	\$35,000
Increased Capability (revenue per day)	\$68,000 – \$75,000	\$227,000	\$58,000	\$72,000
Lead Time to bring increased capacity	2 weeks	Coming online end of Jan 25	3 weeks	3 weeks



<sup>1</sup>Assumes operating at full capacity across 252 days a year


A photograph of a forest floor covered in moss and several mushrooms. The mushrooms are of various sizes and colors, including red with white spots and brown. The background is a blurred forest with sunlight filtering through the trees, creating a bokeh effect.

**Biocyte**


**Key Market  
Opportunity**

# Growing Domestic Demand for Medicinal Cannabis

Australian Medicinal Cannabis Prescriptions<sup>1</sup>



Australian Cannabis Market<sup>2</sup>



- Medicinal CBD & THC products are seeing strong growth in Australia, driven by:
  - Shifts in legality** – legalisation of the controlled use of THC & CBD products
  - Scientific backing** – increased reputable scientific research being conducted
  - Product innovation** – ability to provide precise dosing & varied formulations
  - Increased access** – improved pathways have increased adoption by practitioners


- Market projections suggest that the edible segment, including pastilles, could grow from 1% of the Australian medical cannabis market to more than 20% by 2030..
- GMP-certified THC & CBD pastilles in Australia are emerging as one of the most popular delivery methods for medical cannabis.
- Bioxyne is beginning to benefit significantly from a shift in demand for cannabis pastilles (away from oils) as a preferred method of delivery for patients.

# Cannabis & CBD Market in Europe

Europe's medical cannabis market continues to see strong growth, presenting BXN with a significant opportunity to expand manufacturing, supply and distribution capabilities

## Legislation & Regulation of Cannabis in Europe<sup>1</sup>

- Prescription legal; Adult use legal
- Prescription legal; Adult use decriminalised
- Prescription legal; Adult use illegal
- Prescription illegal



## BLS Europe Growth Opportunity<sup>3,4</sup>

### Germany



- Sales expected to grow from €420m in 2024 to +€1bn by 2028
- Canada accounts for 56% of imported medicinal cannabis
- >12m regular cannabis users

### UK




- Limited public reimbursement, with access almost exclusively through private clinics
- Over 77 cultivators supplying the market
- >9m regular cannabis users

### Czechia



- New Manufacturing & Distribution Facility
- BLS to build Europe's leading novel medicines manufacturing lab
- Existing Czechia operations with manufacturing, warehouse, storage, distribution and sales to whole of EU & UK
- Fully PICs EU GMP accredited

## Sales of CBD in Europe by Product Type<sup>4</sup>



A photograph of cannabis plants in a greenhouse. The plants are green with serrated leaves and developing buds. A white plastic mesh is visible in the foreground, partially obscuring the plants. The lighting is bright, highlighting the texture of the leaves and the structure of the buds.

**Biocyte**



# Financial Overview



# Cash Flow Positive

**Strong outlook for remainder of FY25 and beyond, following execution of significant contracts, providing revenue potential of over \$20m p.a., with customer base continuing to build**

- Bioxyne has delivered positive cash flow of \$1.2m in Q1 FY25, with cash receipts of \$5.8m
- Further investment into production capability during Q2 CY25 has enabled manufacturing output to be increased by 3x current levels, positioning BLS favourably to secure additional supply contracts
- Bioxyne has implemented a significant cost restructure program and strategic refresh aimed at right-sizing BXN’s cost base and driving concentrated growth in key verticals
- Across the last 12 months, BXN has successfully diversified revenue streams in healthcare/wellness sector, taking advantage of significant industry tailwinds
- Cash on hand at the end of the Q1 FY25 of \$1.8m



**Strong performance from provision of psychoactive medicines, supplements and foods made from cannabis, psilocybin & MDMA**

**~\$9.66m**

Total Revenue for FY24

**~\$4.6m**


Revenue for Q1 FY25  
(July-2024)

**~36%**

FY24 Gross Profit Margin  
after selling costs, up from  
28% in FY23

**\$20m+**


FY25 Target Revenue



**Bioxyme**

**Appendix**

**BROAD SPECTRUM CBD**

GOODNIGHT by: 

**DR. WATSON**

**FLUID SUPPLEMENT**  
DESIGNED AS A SUBSTITUTE FOR A VARIETY  
OF ALCOHOLIC BEVERAGES

Flavor:  
LEMON, CHAMOMILE & PEPPERMINT

Concentration:  
1000 (100%)      Volume: 20ML      CBD per ml:  
2.00mg


  
**DR WATSON**

(Get Shiit(ake) Done)

**GSD COMPLEX**  
Mushroom Complex

450 mg Capsules  
60 Caps | 30 day supply

# Experienced Leadership Team



**Mr. Anthony Ho**

*B. Com (UNSW), CA, FAICD, FCIS, FGIA*  
Non-executive Chairman



**Samuel Watson**

*BSc Finance and Economics*  
Managing Director



**Jason Hine**

*BA Economics and Commerce*  
Executive Director




**Guy Robertson**

*B. Com (Hons.) CA*  
CFO & Company Secretary

- Tony is an experienced company director and is currently a director and chairman of a number of listed ASX companies.
- Tony was executive director of sales and distribution company Arthur Yates & Co Limited, as well as Finance Director/CFO of listed retailers on the ASX – M. S. McLeod Holdings Limited (Downtown Duty Free), Galore Group Limited (Barbeques Galore) and Brazin Limited (Bras N Things, Sanity Music).
- Prior to joining commerce, Tony was a partner of Cox Johnston & Co, Chartered Accountants which has since merged with Ernst & Young.
- Samuel Watson was appointed to the Board on 19 May 2023.
- Sam is the founder and CEO of Breathe Life Sciences (BLS). Since establishing BLS and the Dr Watson® Brand in 2018, BLS quickly became a significant player in the health and wellness industry in Europe, UK and Japan. In 2020, BLS entered the Australian market and has grown rapidly into the market leading manufacturer of novel medicines such as MDMA, Psilocybin, and Cannabis.
- Sam is the CEO and founder of Breathe International Ltd, which became Bioxyne's largest shareholder following its all-share acquisition of BLS in 2023.
- Jason was previously the GM Commercial Operations for ECS Botanics Limited, Australia's largest medicinal cannabis and hemp food wellness business.
- The ECS food and wellness business delivers high-quality Tasmania-grown/sourced hemp food and wellness products into the Australian grocery sector via large grocery chains, regional distributors, and a growing bulk supply and B2C channel.
- Jason has been CEO, COO and Managing Director of a number of companies in various industries over a 30-year career.
- Guy is an experienced finance executive, having held the positions of Director, Company Secretary and Chief Financial Officer of both private and ASX-listed companies in Australia and Hong Kong.
- Guy held senior roles in the Jardine Matheson Group of Companies, including General Manager Finance of Franklins Limited, Chief Operating Officer of Colliers International Asia Pacific and Managing Director (NSW) Jardine Lloyd Thompson.

# Corporate Overview



## CORPORATE SNAPSHOT (15/11/2024)

<b>Shares on Issue</b>	~2,049m
<b>Options &amp; Performance Rights</b>	42.9m
<b>Share price</b>	\$0.012
<b>Market capitalisation</b>	\$24.6m
<b>52-week high</b>	\$0.021
<b>52-week low</b>	\$0.004

## MAJOR SHAREHOLDERS

Shareholder	Shares (m)	%
Breathe International Ltd	576,268,527	28.16
Kirkman Trading Ltd	157,805,604	7.71
Ian Edward Owles	132,488,966	6.47
Global Cr Holdings Ltd	114,050,086	5.57
Bpmgmt Ltd	79,493,379	3.88
Nam Hoat Chua	63,574,013	3.11
Zonetech Wellness Ltd	57,732,857	2.82
Peng-hyang Ng	51,500,000	2.52
Paramount Star Investments Limited	36,000,000	1.76



**Bioxyne**

## Contact:

Samuel Watson – Managing Director  
[info@bioxyne.com](mailto:info@bioxyne.com)

James Emonson – Corporate Advisor, Alpine Capital  
[jemonson@alpinecapital.au](mailto:jemonson@alpinecapital.au)